Study design In this research, clinical trial will be performed in Shanghai Children’s Medical Center and Shanghai Shuguang Hospital in China. A brief flowchart of the entire study is shown in Fig.1, and the schedule of events is provided in Fig. 2.
Objectives
- The primary research objective is to evaluate the efficacy and safety of the external use of mirabilite to prevent post-ERCP pancreatitis in children.
- The secondary research objectives include to (a) assess the efficacy of mirabilite to relieve abdominal pain in children after ERCP, (b) the effect of mirabilite on intestinal barrier function and (c) pro-inflammatory reaction.
Study populations
Patients who planned to undergo ERCP in the participated hospitals will be invited to the study. A screening session and physical examination prior to inclusion will be conducted by a medical doctor according to the following criteria.
An investigator who is masked to treatment allocation records the patient demographics, post-ERCP adverse events and follow-up data and the procedure-related parameters including cannulation methods, numbers of cannulation attempts, and inadvertent pancreatic duct cannulation, pancreatography, and prophylactic placement of pancreatic duct stent.
Inclusion criteria
- Ages: 0-14 years.
- Planned for diagnostic or therapeutic ERCP.
- Blood pancreatin level before ERCP within normal limits (amylase: 30-110u/l, blood lipase: 23-300u/l).
- Informed consent obtaining from the guardians of all patients, and assent obtaining from patients greater than 10 years of age.
Exclusion criteria
- Organic gastrointestinal disease such as upper digestive tract stenosis or obstruction.
- Pancreatitis or use of pancreatic enzyme medication within 7 days.
- Cardiovascular, hepatic, renal, cerebrovascular disease or hematopoietic system disease.
- Dermatological disorders such as fresh abdominal wounds, skin lesions, or angioma. Allergy to contrast agents or mirabilite.
Intervention
Surgical details All pediatric patients undergo a comprehensive review and specialist consultations before ERCP. This process aims to ensure an objective and comprehensive analysis, as well as the appropriateness of ERCP, and to rule out contraindications to endoscopy. Patients are asked to undergo routine preoperative laboratory testing (complete blood count, coagulation, blood amylase and lipase concentrations, and hepatic function markers), upper abdominal ultrasonography, computed tomography (CT), magnetic resonance cholangiopancreatography (MRCP), and iodine allergy testing.
Each patient is required to fast for 12 hours before surgery. Duodenoscopy is performed using the JF240V devices (Olympus Corp, Tokyo, Japan). ERCP is conducted by an experienced digestive endoscopy specialist who had performed >30000 ERCPs. The following procedures are completed under radiographic guidance: endoscopic sphincterotomy, balloon dilation, stone extraction, and stenting and naso-pancreatic or naso-bilary drainage tube placement.
Standard post-ERCP treatment Standard treatment will be administered for post-ERCP pancreatitis of both groups, including fasting, pancreatic enzyme control, and fluid and electrolyte balance maintenance. Complications such as infection, bleeding, or perforation within 1 month after discharge will be treated accordingly.
Intervention group(External use of Mirabilite):Patients in the mirabilite group are administered topical application of mirabilite in bag on the middle and upper abdomen within 30 min before ERCP till 24h after ERCP, during which time the mirabilite is replaced every 4 hours, while those in the control group do not receive any additional intervention. Mirabilite is provided by Shanghai University of Traditional Chinese Medicine.
Mirabilite bag is designed with a rectangular shape and in two sizes based on the projected area of the pancreas of the pediatric patients. Children aged ≤6 years receive bags with dimensions of 17 mm × 14 mm, and those aged >6 years received bags with dimensions of 24 mm × 14 mm. Two layers of medical gauze are sewn into rectangular bags, and with four 8-cm attachment bands are sewn to the two longer sides. The bags are used for the topical application of mirabilite to the abdomen and are attached to the patient’s back using the attachment bands.
Randomisation and masking
In this study, patients will be randomly assigned into two treatment groups by 1:1 ratio using a block randomization stratified by centres. The randomization is performed before ERCP (about 7h before ERCP, usually on the morning of the procedure).
Mirabilite will be administered in the procedure room before or after ERCP by one investigator in each site who do not participate in data collection and analysis. These investigators and patients will be instructed not to disclose if or when mirabilite is used. Endoscopists and assistances who participated in ERCP procedures will be masked to group allocation. Investigators who collected demographic or procedure-related data or participated in the assessment of post-ERCP complications will be also masked from group allocation.
Assessments and measurements
Abdominal pain scores (visual analogue scale[VAS] scores)19 will be recorded for all patients at 24h after surgery. On postoperative days 1, 2 and 3, TNF-α, IL-6, IL-8, diamine oxidase, blood D-lac, and endotoxin of serum will be measured. TNF-α, IL-6, IL-8 will be determined using the ELISA method (sandwich ELISA format). Diamine oxidase will be determined by spectrophotometry (Nanjing Jiancheng Bioengineering Institute, Nanjing, China). D-lac will be determined using modified enzymatic spectrophotometry (Nanjing Jiancheng Bioengineering Institute, Nanjing, China). The quantitative determination of endotoxin will be performed with a limulus kit (Sigma, St Louis, MO, USA).
According to the criteria diagnosis of post-ERCP pancreatitis, serum amylase levels and upper abdominal ultrasonography will be measured 24 h after ERCP.
Outcomes
Primary outcome
The primary outcome is the incidence of post-ERCP pancreatitis at 24h after surgery. The post-ERCP pancreatitis (PEP) is defined if a children after ERCP met 2 of the 3 following criteria: classical abdominal pain, a plasma amylase or lipase concentration exceeding 3 times the normal upper limit at 24 hours postoperatively, and radiographic (B-type ultrasonography or CT) suggestive of pancreatitis.
Secondary outcomes: Several secondary outcome measures are also recorded. Abdominal pain is measured 24 h after ERCP using a visual analogue scale (VAS), as follows: 0 points, no tenderness, no pain; 1-3 points, mild but tolerable discomfort and pain; 4-6 points, sleep quality affected by tolerable discomfort and pain; and 7-10 points, strong discomfort and intolerable pain that severely affects sleep quality. The intestinal barrier function assessed by diamine oxidase, D-lactic and endotoxin and proinflammatory cytokine assessed by concentrations of TNF-α, IL-6, and IL-8 are recorded. Inpatient days, the rate of mortality and transfer to the ICU because of severe PEP are also recorded.Safety endpoints
Patients are monitored for adverse reactions to mirabilite, including skin damage and diarrhea. The following adverse reactions to ERCP are also monitored: post-surgical intestinal perforation, bleeding, bile duct infection, and other procedure-related complications requiring an extension of the hospital stay. Patients are followed up for 1 month postoperatively. Detailed definitions for other adverse events are provided in Table 120.
Table 1: Consensus criteria for ERCP complications
|
Mild
|
Moderate
|
Severe
|
Bleeding
|
Clinical evidence of bleeding (i.e., not just endoscopic); Hb level drop <3 g, and no need for transfusion
|
Transfusion:≤4 units; no angiographic intervention or surgery
|
Transfusion> 5 units or intervention (angiographic or surgical)
|
Perforation
|
Possible, or only very slight leak of fluid or contrast dye; treatable by fluids and suction for ≤ 3 days
|
Any definite perforation treated medically for 4-10 d
|
Medical treatment for more than 10 d, or intervention (percutaneous or surgical
|
Infection (cholangitis)
|
>38°C 24-48 hr
|
Febrile or septic illness requiring more than 3 d of hospital treatment or endoscopic or percutaneous intervention
|
Septic shock or surgery
|
Sample size estimation and statistical Analysis
In our previous pilot study, the incidence of post-ERCP pancreatitis in control group was 26% and the incidence in mirabilite group was 16%. The sample size was 260 subjects per group with a of 0.05 and statistical power of 0.8.
We will report our results according to the CONSORT 2010 Statement. The data of all patients who underwent randomization will be analyzed. The qualitative variables will be presented as absolute numbers and proportions. Quantitative variables will be presented as mean ±SD or medians and IQRs as appropriate. The primary endpoint, the incidence of PEP will be shown in absolute frequency and ORs with 95CI, and compared by χ² tests. The secondary endpoints between the two groups will be compared by Mann Whitney U test or t-test as appropriate. All tests are two-sided, and a p value of less than 0.05 is considered statistically significant. Subgroup analysis will be performed according to the patient demographics (age, sex, centre, et al) and the procedure-related parameters. Missing values will be imputed with multiple imputation under the assumption of missing at random. All statistical analyses will be performed with R (version 3.5.1).